Xiaoming Zhao
Research Subjects
Xiaoming Zhao has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Anran Li
National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China
1 shared publicationChenfei Kong
Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, China
1 shared publicationChengyan Xu
Center for Reproductive Medicine, Provincial Hospital Affiliated to Shandong University, National Research Center for Assisted Reproductive Technology and Reproductive Genetics, China
1 shared publicationCong Chen
National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China
1 shared publicationDavis C. Drinkwater
From the Departments of Medicine (G.G.M., S.F.D., D.B.C., P.P., X.-M.Z.), Pathology (J.B.A.), and Surgery (V.S.R., D.C.D., R.N.P.), Vanderbilt University Medical School, Nashville, Tenn. Dr Zhao is now at the Division of Cardiology, Brigham and Women’s Hospital, Boston, Mass
1 shared publicationDonald B. Chomsky
From the Departments of Medicine (G.G.M., S.F.D., D.B.C., P.P., X.-M.Z.), Pathology (J.B.A.), and Surgery (V.S.R., D.C.D., R.N.P.), Vanderbilt University Medical School, Nashville, Tenn. Dr Zhao is now at the Division of Cardiology, Brigham and Women’s Hospital, Boston, Mass
1 shared publication
Latest Publications
- Open Access
- 16 July 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102098
Analysis of the therapeutic effect and potential mechanism of Fe3O4-polydopamine nanoparticles in enhancing mesenchymal stem cells therapy for pulmonary fibrosis
- 16 July 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102098
Open AccessAnalysis of the therapeutic effect and potential mechanism of Fe3O4-polydopamine nanoparticles in enhancing mesenchymal stem cells therapy for pulmonary fibrosis
- Open Access
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 29, 0224
Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Oxidative Damage via the miR-191-5p/DAPK1/AKT Axis in Type 2 Diabetes
Human umbilical cord mesenchymal stem cell extracellular vesicles (hucMSC-EVs) exhibit remarkable potential for alleviating type 2 diabetes mellitus (T2DM). However, the role of hucMSC-EVs in T2DM, particularly concerning oxidative damage to pancreatic β cells, remains underexplored. This study utilized a high-fat diet and streptozotocin (STZ)-induced T2DM mouse model and an STZ-induced INS-1 cell damage model to investigate the effects and mechanisms of hucMSC-EVs. In the T2DM mouse model, hucMSC-EVs effectively lowered blood glucose levels, improved lipid metabolism disorders, and preserved liver function. Moreover, hucMSC-EVs enhanced insulin sensitivity and mitigated oxidative damage. Histological analysis confirmed that hucMSC-EVs marked alleviated liver, kidney, and pancreatic tissue damage. In vitro studies demonstrate that hucMSC-EVs enhance glucose absorption and glycogen synthesis in an insulin-resistant HepG2 model and stimulated insulin secretion in INS-1 cells under high-glucose conditions. In the STZ-induced INS-1 oxidative damage model, hucMSC-EVs protect against oxidative damage by increasing antioxidant enzyme activities, reducing reactive oxygen species production, and decreasing cell apoptosis. The effects were partially mediated by the activation of the phosphatidylinositol 3-kinase (PI3K)/AKT and signal transducer and activator of transcription (STAT) signaling pathways, as well as the up-regulation of key antioxidant proteins such as Nrf2, SOD1, and Bcl2. Further research revealed that miR-191-5p, which is enriched in hucMSC-EVs, targets DAPK1 to activate the PI3K/AKT pathway, thereby contributing to the protective effects against oxidative damage. These findings highlight the critical role and underlying mechanisms of hucMSC-EVs in ameliorating metabolic dysfunction in T2DM, particularly the protective effects against oxidative damage, thus providing a novel strategy for the treatment of T2DM.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 29, 0224
Open AccessUmbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Oxidative Damage via the miR-191-5p/DAPK1/AKT Axis in Type 2 Diabetes
Human umbilical cord mesenchymal stem cell extracellular vesicles (hucMSC-EVs) exhibit remarkable potential for alleviating type 2 diabetes mellitus (T2DM). However, the role of hucMSC-EVs in T2DM, particularly concerning oxidative damage to pancreatic β cells, remains underexplored. This study utilized a high-fat diet and streptozotocin (STZ)-induced T2DM mouse model and an STZ-induced INS-1 cell damage model to investigate the effects and mechanisms of hucMSC-EVs. In the T2DM mouse model, hucMSC-EVs effectively lowered blood glucose levels, improved lipid metabolism disorders, and preserved liver function. Moreover, hucMSC-EVs enhanced insulin sensitivity and mitigated oxidative damage. Histological analysis confirmed that hucMSC-EVs marked alleviated liver, kidney, and pancreatic tissue damage. In vitro studies demonstrate that hucMSC-EVs enhance glucose absorption and glycogen synthesis in an insulin-resistant HepG2 model and stimulated insulin secretion in INS-1 cells under high-glucose conditions. In the STZ-induced INS-1 oxidative damage model, hucMSC-EVs protect against oxidative damage by increasing antioxidant enzyme activities, reducing reactive oxygen species production, and decreasing cell apoptosis. The effects were partially mediated by the activation of the phosphatidylinositol 3-kinase (PI3K)/AKT and signal transducer and activator of transcription (STAT) signaling pathways, as well as the up-regulation of key antioxidant proteins such as Nrf2, SOD1, and Bcl2. Further research revealed that miR-191-5p, which is enriched in hucMSC-EVs, targets DAPK1 to activate the PI3K/AKT pathway, thereby contributing to the protective effects against oxidative damage. These findings highlight the critical role and underlying mechanisms of hucMSC-EVs in ameliorating metabolic dysfunction in T2DM, particularly the protective effects against oxidative damage, thus providing a novel strategy for the treatment of T2DM.
- 30 July 2015
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 41 (10) , 1569-1576
Hysteroscopy prior to repeat embryo transfer may improve pregnancy outcomes for asymptomatic women with repeated implantation failure
Aim: The aim of this study was to evaluate the efficacy of hysteroscopy (HS) in detecting intrauterine abnormalities prior to repeat embryo transfer and improving pregnancy outcomes in asymptomatic women with repeated implantation failure (RIF).Material and Methods: A prospective cohort study was conducted involving 672 asymptomatic RIF women from a Chinese university hospital. Pregnancy outcomes between the HS (subdivided into patients with and without intrauterine abnormalities) and non‐HS groups were compared.Results: The incidence of intrauterine abnormalities in the HS group was 37.13%. The most common abnormalities included endometrial polyps or polypoid endometrium, endometrial hyperplasia and intrauterine adhesions. Clinical pregnancy and implantation rates in the HS group were significantly higher than in the non‐HS group (41.92% vs 32.25%; 23.82% vs 18.60%, respectively). There were no significant differences in early abortion, ectopic pregnancy, late abortion and live birth rates. The clinical pregnancy and implantation rates in both HS subgroups were significantly higher when compared to the non‐HS group, whereas there were no significant differences between the subgroups.Conclusion: HS improved pregnancy outcomes in women with or without intrauterine abnormalities. HS may be routinely performed before repeat embryo transfer in RIF women.
- 30 July 2015
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 41 (10) , 1569-1576
Hysteroscopy prior to repeat embryo transfer may improve pregnancy outcomes for asymptomatic women with repeated implantation failure
Aim: The aim of this study was to evaluate the efficacy of hysteroscopy (HS) in detecting intrauterine abnormalities prior to repeat embryo transfer and improving pregnancy outcomes in asymptomatic women with repeated implantation failure (RIF).Material and Methods: A prospective cohort study was conducted involving 672 asymptomatic RIF women from a Chinese university hospital. Pregnancy outcomes between the HS (subdivided into patients with and without intrauterine abnormalities) and non‐HS groups were compared.Results: The incidence of intrauterine abnormalities in the HS group was 37.13%. The most common abnormalities included endometrial polyps or polypoid endometrium, endometrial hyperplasia and intrauterine adhesions. Clinical pregnancy and implantation rates in the HS group were significantly higher than in the non‐HS group (41.92% vs 32.25%; 23.82% vs 18.60%, respectively). There were no significant differences in early abortion, ectopic pregnancy, late abortion and live birth rates. The clinical pregnancy and implantation rates in both HS subgroups were significantly higher when compared to the non‐HS group, whereas there were no significant differences between the subgroups.Conclusion: HS improved pregnancy outcomes in women with or without intrauterine abnormalities. HS may be routinely performed before repeat embryo transfer in RIF women.
- Open Access
- 19 March 2012
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 24 (6) , 630-633
Mutations in WNT4 are not responsible for Müllerian duct abnormalities in Chinese women
- 19 March 2012
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 24 (6) , 630-633
Open AccessMutations in WNT4 are not responsible for Müllerian duct abnormalities in Chinese women
- Open Access
- 14 December 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (24) , 2396-2399
Longitudinal Analysis of Fibroblast Growth Factor Expression After Transplantation and Association With Severity of Cardiac Allograft Vasculopathy
Background —Vascular smooth muscle cell growth factors are postulated to contribute to cardiac allograft vasculopathy (CAV). Few data quantitatively address the timing, location, or stimuli for growth factor expression and relationship to CAV. Methods and Results —Acidic fibroblast growth factor (aFGF) mRNA expression was determined in serial endomyocardial biopsies during the first year after transplantation. Patients with high levels of aFGF mRNA and elevations after the early posttransplant period had significantly more severe CAV than patients with low aFGF and no late elevations. Conclusions —Parenchymal aFGF expression varies between patients and in the same patient over time and correlates with development of CAV.
- 14 December 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (24) , 2396-2399
Open AccessLongitudinal Analysis of Fibroblast Growth Factor Expression After Transplantation and Association With Severity of Cardiac Allograft Vasculopathy
Background —Vascular smooth muscle cell growth factors are postulated to contribute to cardiac allograft vasculopathy (CAV). Few data quantitatively address the timing, location, or stimuli for growth factor expression and relationship to CAV. Methods and Results —Acidic fibroblast growth factor (aFGF) mRNA expression was determined in serial endomyocardial biopsies during the first year after transplantation. Patients with high levels of aFGF mRNA and elevations after the early posttransplant period had significantly more severe CAV than patients with low aFGF and no late elevations. Conclusions —Parenchymal aFGF expression varies between patients and in the same patient over time and correlates with development of CAV.